Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 42

1.

Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schröder FH, Zappa M.

Eur Urol. 2015 Mar 16. pii: S0302-2838(15)00207-9. doi: 10.1016/j.eururo.2015.02.042. [Epub ahead of print]

PMID:
25791513
2.

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators.

Lancet. 2014 Dec 6;384(9959):2027-35. doi: 10.1016/S0140-6736(14)60525-0. Epub 2014 Aug 6.

PMID:
25108889
3.

European breast cancer service screening outcomes: a first balance sheet of the benefits and harms.

Paci E, Broeders M, Hofvind S, Puliti D, Duffy SW; EUROSCREEN Working Group.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1159-63. doi: 10.1158/1055-9965.EPI-13-0320.

4.

A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality.

Zappa M, Puliti D, Hugosson J, Schröder FH, van Leeuwen PJ, Kranse R, Auvinen A, Carlsson S, Kwiatkowski M, Nelen V, Paez Borda A, Roobol MJ, Villers A.

Eur Urol. 2014 Sep;66(3):401-3. doi: 10.1016/j.eururo.2013.12.055. Epub 2014 Jan 7.

PMID:
24412230
5.

[Tailored Breast Screening Trial (TBST)].

Paci E, Mantellini P, Giorgi Rossi P, Falini P, Puliti D; TBST Working Group.

Epidemiol Prev. 2013 Jul-Oct;37(4-5):317-27. Italian.

PMID:
24293498
6.

Decreasing incidence of late-stage breast cancer after the introduction of organized mammography screening in Italy.

Foca F, Mancini S, Bucchi L, Puliti D, Zappa M, Naldoni C, Falcini F, Gambino ML, Piffer S, Sanoja Gonzalez ME, Stracci F, Zorzi M, Paci E; IMPACT Working Group.

Cancer. 2013 Jun 1;119(11):2022-8. doi: 10.1002/cncr.28014. Epub 2013 Mar 15.

7.

Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review.

Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, Paci E; EUROSCREEN Working Group.

J Med Screen. 2012;19 Suppl 1:42-56. Review.

PMID:
22972810
8.

Codon 72 polymorphism of p53 and HPV type 16 E6 variants as risk factors for patients with squamous epithelial lesion of the uterine cervix.

Burroni E, Bisanzi S, Sani C, Puliti D, Carozzi F.

J Med Virol. 2013 Jan;85(1):83-90. doi: 10.1002/jmv.23417. Epub 2012 Nov 4.

PMID:
23124863
9.

Breast cancer screening: are we seeing the benefit?

Puliti D, Zappa M.

BMC Med. 2012 Sep 20;10:106.

10.

Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.

Caldarella A, Puliti D, Crocetti E, Bianchi S, Vezzosi V, Apicella P, Biancalani M, Giannini A, Urso C, Zolfanelli F, Paci E.

J Cancer Res Clin Oncol. 2013 Feb;139(2):181-5. doi: 10.1007/s00432-012-1304-1. Epub 2012 Sep 9.

PMID:
22961208
11.

Balancing harms and benefits of service mammography screening programs: a cohort study.

Puliti D, Miccinesi G, Zappa M, Manneschi G, Crocetti E, Paci E.

Breast Cancer Res. 2012 Jan 9;14(1):R9.

12.

[Cancer incidence in Italian natives and in first-generation immigrants to Italy].

Manneschi G, Crocetti E, Puliti D, Zappa M, Sacchettini C, Paci E.

Epidemiol Prev. 2011 Sep-Dec;35(5-6):292-6. Italian.

PMID:
22166775
13.

Minor influence of self-selection bias on the effectiveness of breast cancer screening in case-control studies in the Netherlands.

Paap E, Verbeek A, Puliti D, Broeders M, Paci E.

J Med Screen. 2011;18(3):142-6. doi: 10.1258/jms.2011.011027.

PMID:
22045823
14.

[End-of-life care and end-of-life medical decisions: the ITAELD study].

Miccinesi G, Puliti D, Paci E.

Epidemiol Prev. 2011 May-Aug;35(3-4):178-87. Italian.

PMID:
21914914
15.

Overdiagnosis in breast cancer: design and methods of estimation in observational studies.

Puliti D, Miccinesi G, Paci E.

Prev Med. 2011 Sep;53(3):131-3. doi: 10.1016/j.ypmed.2011.05.012. Epub 2011 Jun 2.

PMID:
21658405
16.

Does an organised screening programme reduce the inequalities in breast cancer survival?

Puliti D, Miccinesi G, Manneschi G, Buzzoni C, Crocetti E, Paci E, Zappa M.

Ann Oncol. 2012 Feb;23(2):319-23. doi: 10.1093/annonc/mdr121. Epub 2011 Apr 22.

17.

Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.

Carozzi FM, Burroni E, Bisanzi S, Puliti D, Confortini M, Giorgi Rossi P, Sani C, Scalisi A, Chini F.

J Clin Microbiol. 2011 Apr;49(4):1446-51. doi: 10.1128/JCM.02311-10. Epub 2011 Feb 16.

18.

More on screening mammography.

Puliti D, Miccinesi G, Zappa M.

N Engl J Med. 2011 Jan 20;364(3):284-5; author reply 286. doi: 10.1056/NEJMc1011881#SA6. No abstract available.

PMID:
21247319
19.

A simple method to estimate the episode and programme sensitivity of breast cancer screening programmes.

Zorzi M, Guzzinati S, Puliti D, Paci E; IMPACT working group.

J Med Screen. 2010;17(3):132-8. doi: 10.1258/jms.2010.009060.

PMID:
20956723
20.

Breast cancer screening case-control study design: impact on breast cancer mortality.

Paap E, Verbeek AL, Puliti D, Paci E, Broeders MJ.

Ann Oncol. 2011 Apr;22(4):863-9. doi: 10.1093/annonc/mdq447. Epub 2010 Oct 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk